Quantcast
Last updated on April 24, 2014 at 1:21 EDT

Latest Pharmaceuticals policy Stories

2014-03-24 08:28:48

DUBLIN, Ohio, March 24, 2014 /PRNewswire/ -- The Cardinal Health Foundation is inviting non-profit organizations in 18 U.S. locations and Puerto Rico to apply for grant funding to support local efforts to prevent the abuse and misuse of prescription medications. This marks the fifth consecutive year that the Cardinal Health Foundation's Prescription Drug Abuse and Misuse Prevention Grant Program will provide funding to help non-profit organizations raise awareness and promote education about...

2014-03-23 23:00:49

Top 10 Drug Delivery Technologies Market research report intensively evaluates drug delivery technologies with respect to revenues, growth, therapeutic areas, patents registered and industry focus to arrive at top 10 drug delivery technologies - http://www.marketsandmarkets.com/Market-Reports/top-10-drug-delivery-technologies-112.html. (PRWEB) March 23, 2014 The ‘Global Top 10 Drug Delivery Technologies Market (2010 – 2015)’ analyzes the drug delivery technologies market by the top...

2014-03-22 23:01:14

The industry has some experienced declines in recent years, however, going forward, it is expected to rise. For these reasons, industry research firm IBISWorld has added a report on the Institutional Pharmacies industry to its growing industry report collection. New York, NY (PRWEB) March 22, 2014 Due to the nondiscretionary nature of most of the products and services offered, the $13.6 billion Institutional Pharmacies industry is relatively immune to fluctuations in the macroeconomic...

2014-03-22 12:21:28

DALLAS, March 22, 2014 /PRNewswire/ -- ReportsnReports.com offers "Global Orphan Drug Market Outlook 2018", "Global Orphan Drugs Market 2014-2018" and "Global Orphan Drug Pipeline Analysis" research reports in its store. The returns on investment from orphan drugs are expected to help the pharma companies to overcome the impact of revenue loss due to expiry of patents of blockbuster drugs. The major drivers for companies to increasingly invest in orphan drugs include...

2014-03-20 23:29:36

National network of attorneys initiates offer of no-cost consultations to consumers seeking compensation for allegations of gynecomastia, other side effects. San Diego, CA (PRWEB) March 20, 2014 http://www.resource4thepeople.com/defectivedrugs/risperdal.html Resource4thePeople announced today that its national network of attorneys is now investigating claims over allegations that the antipsychotic medication Risperdal may cause a breast-growth condition known as gynecomastia or other side...

2014-03-20 12:33:37

WASHINGTON, March 20, 2014 /PRNewswire-USNewswire/ -- The National Council on Disability (NCD), an independent federal agency that advises the President, Congress and other federal agencies on disability policy, welcomes the settlement agreement announced March 18 between CVS/pharmacy and the American Council of the Blind, the California Council of the Blind and the American Foundation for the Blind that will make 'ScripTalk' talking prescription labels available to online and mail...

2014-03-19 23:32:31

ALLVETMED Corp announces today of their award by the National Association of Boards of Pharmacy (NABP)receiving the National Vet - VIPPS Accreditation National license. This lists the company as the 17th to receive this license. (PRWEB) March 19, 2014 This award allows ALLVETMED Corp Ltd to operate as an online vet pharmacy at a national level. Vet - VIPPS (Veterinary Verified Internet Pharmacy Practice Sites) accreditation offers online pharmacies the chance to operate online veterinary...

2014-03-19 23:02:33

Pharmaceutical manufacturers are required by the FDA to train personnel in FDA quality system requirements and procedures. Now manufacturers can train their staff for significantly less money, in their own office, with a new training video developed by a former FDA investigator. Falls Church, VA (PRWEB) March 19, 2014 Quality Systems Training DVD for Drugmakers **FDAnews DVD Training Course** http://www.fdanews.com/QualityDrugDVD Pharmaceutical manufacturers are required by the FDA to...

2014-03-19 16:23:48

DUBLIN, March 19, 2014 /PRNewswire/ -- Actavis plc (NYSE: ACT) today announced that it has entered into an agreement with Noven Pharmaceuticals, Inc. to settle all outstanding patent litigation related to Actavis' generic version of Daytrana(® )(Methylphenidate Transdermal System). Daytrana(®) is a CNS stimulant indicated for the treatment of Attention Deficit Hyperactivity Disorder. Under the terms of the agreement, Noven will grant Actavis a non-exclusive, royalty-bearing...

2014-03-19 16:23:38

ATLANTA, March 19, 2014 /PRNewswire/ -- Arbor Pharmaceuticals announced today that the U.S. Food and Drug Administration (FDA) has accepted for filing its second New Drug Application (NDA). The NDA was originally filed with the FDA on December 23, 2013 and officially accepted for filing on February 23, 2014. Arbor's first NDA, Nymalize(®) (nimodipine) oral solution, was approved in May of last year. Arbor has a total of seven other branded projects in development consisting of both...